TechnipFMC plc
$30.74B- Market cap
- $31.31B
- Debt
- +$464.30M
- Cash
- −$1.03B
Capital structure 99% equity / 1% debt · EV / Revenue 3.10x · EV / EBITDA 18.66x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: FTI stock price vs ROIV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Needs ROIV P/E.
Implied fair value · at FTI's multiple
Needs EPS (TTM) is negative, FTI P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FTI FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 3.10x · EV / EBITDA 18.66x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TechnipFMC plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
0.09x
Net debt / EBITDA
Leverage against operating earnings
-0.34x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$1.03B
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SCHLUMBERGER LIMITED/NV
FTI vs SLB
Baker Hughes Co
FTI vs BKR
HALLIBURTON CO
FTI vs HAL
NOV Inc.
FTI vs NOV
Weatherford International plc
FTI vs WFRD
Revolution Medicines, Inc.
FTI vs RVMD
INCYTE CORP
FTI vs INCY
Sarepta Therapeutics, Inc.
FTI vs SRPT
EXELIXIS, INC.
FTI vs EXEL
VERTEX PHARMACEUTICALS INC / MA
FTI vs VRTX
$464.30M
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.